2 Result: Nasdaq:TARS
Buy Ratings: TARS, VICR, SNDX, ENLC, AMZN, UFPT, PEN - Key Upside Potential
June 26th, 2023
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a biopharmaceutical company specializing in ophthalmic therapeutics, has been maintained at a Buy rating by HC Wainwright & Co., who raised the price target from $40 to $44. $TARS closed at $17.15. Read more
Market Buzz: Bullish Narrative for Liquid Media, Tarsus Pharma, Vertiv, and Neogen
June 17th, 2023
Shares of Liquid Media Group Ltd. (Nasdaq: YVR) experienced a notable surge of over 11% in after-hours trading Friday as the company revealed the sale of its wholly-owned subsidiary, IndieFlix Group, for a total purchase price of US$1.2 million. T. Read more
Want To Find Some News?
News By Industries
Recent Post
-
February 27th, 2026February 26th, 2026
Treasury Sanctions Nicaraguan Officials Enabling the Murillo-Ortega Dictatorship's Repression
February 26th, 2026Kansas City Storm Names Cecil Stockdale as Head Coach for 2026 NJCP Season
February 26th, 2026Dallas Stampede Announces Open Tryouts for Scholarship Opportunities
February 25th, 2026
Member Login